Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Shares Outstanding (Weighted Average): 2009-2024

Historic Shares Outstanding (Weighted Average) for Heron Therapeutics (HRTX) over the last 16 years, with Dec 2024 value amounting to $152.1 million.

  • Heron Therapeutics' Shares Outstanding (Weighted Average) rose 1.07% to $153.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $153.3 million, marking a year-over-year increase of 1.07%. This contributed to the annual value of $152.1 million for FY2024, which is 1.35% up from last year.
  • According to the latest figures from FY2024, Heron Therapeutics' Shares Outstanding (Weighted Average) is $152.1 million, which was up 1.35% from $150.1 million recorded in FY2023.
  • Heron Therapeutics' 5-year Shares Outstanding (Weighted Average) high stood at $152.1 million for FY2024, and its period low was $90.9 million during FY2020.
  • Moreover, its 3-year median value for Shares Outstanding (Weighted Average) was $150.1 million (2023), whereas its average is $140.4 million.
  • Data for Heron Therapeutics' Shares Outstanding (Weighted Average) shows a peak YoY climbed of 26.23% (in 2023) over the last 5 years.
  • Yearly analysis of 5 years shows Heron Therapeutics' Shares Outstanding (Weighted Average) stood at $90.9 million in 2020, then rose by 12.20% to $101.9 million in 2021, then grew by 16.63% to $118.9 million in 2022, then increased by 26.23% to $150.1 million in 2023, then increased by 1.35% to $152.1 million in 2024.